Latest Nyr News

Page 1 of 2
Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.
Ada Torres
Ada Torres
21 Oct 2025
Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.
Ada Torres
Ada Torres
29 Sept 2025
Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.
Ada Torres
Ada Torres
16 Sept 2025
Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.
Ada Torres
Ada Torres
22 Aug 2025
Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.
Ada Torres
Ada Torres
14 Aug 2025
Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.
Ada Torres
Ada Torres
6 Aug 2025
Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.
Ada Torres
Ada Torres
4 Aug 2025
Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.
Ada Torres
Ada Torres
31 July 2025
Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.
Ada Torres
Ada Torres
23 July 2025
Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.
Ada Torres
Ada Torres
21 July 2025
Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.
Ada Torres
Ada Torres
14 July 2025
Nyrada’s Phase I clinical trial for its novel drug Xolatryp has cleared safety reviews through four cohorts and will now test higher doses and longer infusions in an expanded trial design.
Ada Torres
Ada Torres
16 June 2025